Heart drug improves or stabilizes heart function in Duchenne muscular dystrophy

March 7, 2017, Nationwide Children's Hospital
heart
Human heart. Credit: copyright American Heart Association

Researchers at The Ohio State University Ross Heart Hospital and Nationwide Children's Hospital have shown early treatment with the heart failure medication eplerenone can improve heart function in young boys with Duchenne muscular dystrophy (DMD) and stabilize heart function in older boys with the disease.

The results of their study are published in Orphanet Journal of Rare Diseases.

The scientists examined the safety and efficacy of longer-term therapy with eplerenone, a diuretic used to treat high blood pressure and . This directly followed their 12-month study of the drug, published in the Lancet Neurology, which showed it slowed the progressive decline in heart function among DMD patients, compared to placebo.

Eleven boys and young men, ages 7 to 25, from the original 12 month study went on to participate in this 24-month trial extension during which all participants received 25 mg of eplerenone daily to treat DMD .

Over two years, researchers examined a sensitive measurement of known as strain. It starts becoming abnormal long before symptoms or other signs of heart disease appear.

"We saw significant improvement in left ventricular systolic function among the younger boys who were newly treated with eplerenone. The older patients who continued eplerenone therapy from the previous trial to this one remained stable," said Dr. Subha Raman, a cardiologist and professor at Ohio State Wexner Medical Center and lead author on the study. "Recognizing that cardiopulmonary failure remains the leading cause of death in this disease, this tells us we should strongly consider early use of this medication in boys with DMD in order to gain the greatest cardiac benefit."

Additionally, the research team reported no one experienced any adverse effects from the drug, such as elevated potassium levels.

DMD is a genetic disorder in which the body lacks dystrophin, a protein that helps keep muscle cells intact. It causes the skeletal and heart muscles to rapidly degenerate and weaken. DMD predominantly affects males. A majority of patients develop heart or respiratory failure, surviving into their 20s or 30s.

"It's important to remember that the heart is a muscle too. If we're to achieve long term improvements in duration and quality of life for patients with DMD, we must strive to understand the associated better. This trial is one small piece of that big puzzle," said Dr. Linda Cripe, a pediatric cardiologist and co-investigator at Nationwide Children's.

This research was inspired by 30-year-old Ryan Ballou of Pittsburgh, a young man with DMD who, along with his father, started BallouSkies to raise awareness and funding for Raman's research of heart disease in patients. BallouSkies and the Parent Project for Muscular Dystrophy financially supported the study.

Explore further: Drug combo slows heart decline in muscular dystrophy

More information: Subha V. Raman et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial, Orphanet Journal of Rare Diseases (2017). DOI: 10.1186/s13023-017-0590-8

Related Stories

Drug combo slows heart decline in muscular dystrophy

December 29, 2014
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online ...

Docs: Heart device might be breakthrough for muscular dystrophy

October 17, 2012
(HealthDay)—A man with Duchenne muscular dystrophy who received a device to help his heart's left ventricle pump blood throughout his body could represent a breakthrough in the treatment of the disease, according to his ...

Drug may improve outcomes after heart attack

March 12, 2013
The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's ...

Eplerenone reduces primary endpoint in acute myocardial infarction patients

April 29, 2014
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect,say the ...

Clinical trial first to test heart drug regimen for Duchenne muscular dystrophy

June 26, 2012
The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease.

Recommended for you

New health calculator can help predict heart disease risk, estimate heart age

July 23, 2018
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health ...

Drug now in clinical trials for Parkinson's strengthens heart contractions in animals

July 20, 2018
A drug currently in clinical trials for treating symptoms of Parkinson's disease may someday have value for treating heart failure, according to results of early animal studies by Johns Hopkins Medicine researchers.

'Good cholesterol' may not always be good

July 19, 2018
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) - also known as 'good cholesterol' - according to a study led by researchers in the University of Pittsburgh Graduate ...

Using adrenaline in cardiac arrests results in less than 1 percent more people leaving hospital alive

July 18, 2018
A clinical trial of the use of adrenaline in cardiac arrests has found that its use results in less than 1% more people leaving hospital alive—but almost doubles the risk of severe brain damage for survivors of cardiac ...

Omega 3 supplements have little or no heart or vascular health benefit: review

July 17, 2018
New evidence published today shows there is little or no effect of omega 3 supplements on our risk of experiencing heart disease, stroke or death.

Researchers discover new genes associated with heart function

July 17, 2018
A new study from an international research team, led by Dr. Yalda Jamshidi at St George's, University of London, has identified new genes associated with heart function and development.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.